Sorafenib vs sunitinib (targeted agent versus targeted agent)
Health‐related quality of life5 · Treatment‐naïve metastatic renal cell carcinoma (any cell type)
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found